Related references
Note: Only part of the references are listed.Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years
N. Penel et al.
ANNALS OF ONCOLOGY (2011)
Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma
S. Tariq Mahmood et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Epithelioid sarcoma expresses epidermal growth factor receptor but gene amplification and kinase domain mutations are rare
Michael J. Cascio et al.
MODERN PATHOLOGY (2010)
VEGF inhibition: insights from preclinical and clinical studies
Yongping Crawford et al.
CELL AND TISSUE RESEARCH (2009)
Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas
Suzanne George et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
Stefan Sleijfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Epithelioid sarcoma: Prognostic factors and survival in a series of patients treated at a single institution
Dario Baratti et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Epithelioid sarcoma: The clinicopathological complexities of this rare soft tissue sarcoma
AJ Spillane et al.
ANNALS OF SURGICAL ONCOLOGY (2000)
Share Paper
